Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
Randomized, double-blind, placebo-controlled trial of once-daily GLP-1 receptor agonist lixisenatide in Asian patients with Type 2 diabetes insufficiently controlled on Basal Insulin with or without sulfonylurea (GetGoal-L-Asia ).